Variational open interest has exceeded $2 billions.
Foresight News reports that, according to official data, the on-chain derivatives protocol Variational's open interest has surpassed 2 billion US dollars. Over one-third of the open interest originates from the traditional market.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Iovance Biotherapeutics Raises 2026 Revenue Guidance
AstraZeneca (AZN.US) invests in Summit (SMMT.US), gaining positive outlooks from JPMorgan and Citi: Cancer drug strategy awaits validation
Analysts from JPMorgan and Citi have welcomed the deal between AstraZeneca and Summit Therapeutics, stating that it aligns with AstraZeneca's cancer strategy.
